SCHEMBL20644543

SCHEMBL20644543

CC[C@@H]([C@@H](C)O)n1ncn(-c2ncc(C(C)C)cc2F)c1=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABCB11 O95342 1/20 0.35
▸ CYP17A1 P05093 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CYP19A1 P11511 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ CYP11B1 P15538 1/20 0.35
▸ CYP11B2 P19099 1/20 0.35
▸ PTGS2 P35354 1/20 0.35
▸ ABCG2 Q9UNQ0 1/20 0.35
▸ CYP8B1 Q9UNU6 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ KCNJ1 P48048 1/20 0.32
▸ DGAT1 O75907 1/20 0.30
▸ GRIN1 Q05586 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20644506 0.88 ABCB11 (0.36) ABCB11CYP17A1CYP3A4CYP19A1CYP2C9
SCHEMBL20644563 0.78 MAPT (0.37) ABCB11CYP17A1CYP3A4CYP19A1CYP2C9
SCHEMBL25160279 0.78 MAPT (0.37) ABCB11CYP17A1CYP3A4CYP19A1CYP2C9
SCHEMBL20644496 0.75 MAPT (0.50) ABCB11CYP17A1CYP3A4CYP19A1CYP2C9
SCHEMBL20652848 0.75 MAPT (0.50) ABCB11CYP17A1CYP3A4CYP19A1CYP2C9
SCHEMBL25160125 0.70 MAPT (0.37) ABCB11CYP17A1CYP3A4CYP19A1CYP2C9
SCHEMBL20644374 0.70 — —
SCHEMBL20644439 0.70 PRMT5 (0.37) DGAT1
SCHEMBL23709213 0.69 MAPT (0.51) ABCB11CYP17A1CYP3A4CYP19A1CYP2C9
SCHEMBL25160033 0.69 MAPT (0.51) ABCB11CYP17A1CYP3A4CYP19A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10464922-B2 Metalloenzyme inhibitor compounds NQP 1598, LTD. (US) 2019-11-05 — — US disclosed
US-20190016700-A1 METALLOENZYME INHIBITOR COMPOUNDS NQP 1598, LTD. (KY) 2019-01-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190016700-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO ABCB11 1369/4885CYP17A1 649/4885CYP3A4 558/4885
US-10464922-B2 Metalloenzyme inhibitor compounds MMEL1, GPX1, MPO ABCB11 1369/4885CYP17A1 649/4885CYP3A4 558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback